SCHEMBL6264690

SCHEMBL6264690

COC(=O)CCCC(=O)NCCCN1CCN(c2ccccc2OC)CC1

nearest known ligand 0.77

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.72
DRD3 P35462 4/20 0.72
HTR1A P08908 5/20 0.68
HTR7 P34969 4/20 0.68
ADRA1A P35348 2/20 0.68
DRD4 P21917 2/20 0.64
ADRA1D P25100 1/20 0.64
ADRA1B P35368 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6238933 0.92 DRD2 (0.72) DRD2DRD3HTR1AHTR7ADRA1A
SCHEMBL11083371 0.87 HTR1A (0.72) DRD2DRD3HTR1AHTR7
Hydrochloric Acid SCHEMBL11089079 0.85 HTR1A (0.72) DRD2HTR1AHTR7
SCHEMBL3162960 0.84 DRD2 (0.76) DRD2DRD3DRD4
SCHEMBL14761584 0.81 DRD2 (0.94) DRD2DRD3HTR1AADRA1ADRD4
SCHEMBL19580052 0.81 DRD2 (0.81) DRD2DRD3HTR1AADRA1ADRD4
SCHEMBL9653869 0.81 DRD2 (0.78) DRD2DRD3HTR1AADRA1ADRD4
SCHEMBL7869518 0.81 DRD2 (1.00) DRD2DRD3DRD4
SCHEMBL27966706 0.81 DRD2 (1.00) DRD2DRD3DRD4
SCHEMBL7703653 0.80 DRD2 (0.83) DRD2DRD3HTR1AHTR7ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005018643-A1 METABOLITES OF 1-{3-4`4-(2-METHOXYPHENYL) PIPERAZIN-1-YL!-PROPYL}-PIPERIDINE-2, 6-DIONE FOR USE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA RANBAXY LABORATORIES LIMITED (IN) 2005-03-03 WO claimed
WO-2005018643-A1 METABOLITES OF 1-{3-4`4-(2-METHOXYPHENYL) PIPERAZIN-1-YL!-PROPYL}-PIPERIDINE-2, 6-DIONE FOR USE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA RANBAXY LABORATORIES LIMITED (IN) 2005-03-03 WO disclosed